HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

Summary

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Conditions

• Hip Fractures
• Myocardial Injury

Interventions

OTHER

Accelerated medical clearance and surgery

Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.

Sponsors & Collaborators

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

  collaborator NIH

• Population Health Research Institute

  lead OTHER

Principal Investigators

• Flavia Borges, M.D · Population Health Research Institute

• Gerard Slobogean, M.D · University of Maryland, Baltimore

• Robert Feibel, M.D · The Ottawa Hospital

• PJ Devereaux, M.D · Population Health Research Institute

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

45 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-11-22

Primary Completion

2027-02-28

Completion

2027-05-31

Countries

• United States
• Australia
• Belgium
• Brazil
• Canada
• Chile
• Finland
• Hong Kong
• India
• Italy
• Malaysia
• Mexico
• Nepal
• Netherlands
• Pakistan
• Poland
• Saudi Arabia
• South Africa
• Spain

Study Locations